Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trialDiwakar Davar, Janis M. Taube, Robert M. Morrison et al.|Cancer Cell|2024Cited by 60
Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced MelanomaYana G. Najjar, Ahmad A. Tarhini, Amy Rose et al.|Clinical Cancer Research|2021Cited by 26
Supplementary figure legend 1 from Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced MelanomaYana G. Najjar, Ahmad A. Tarhini, Dustin McCurry et al.|Unknown|2023Cited by 0
Supplementary Figure S2 from Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced MelanomaYana G. Najjar, Ahmad A. Tarhini, Dustin McCurry et al.|Unknown|2023Cited by 0
Supplementary Figure S1 from Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced MelanomaYana G. Najjar, Ahmad A. Tarhini, Dustin McCurry et al.|Unknown|2023Cited by 0